TBX2 and cancer: Taken together, these studies support the development of TBX2 as a predictive biomarker of treatment responses, particularly in the case of platinum-based compounds, and suggest that combining a TBX2-targeted approach with chemotherapies like cisplatin has the potential to enhance the overall success of current cancer treatments.